NEW YORK, January 7, 2014 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), Molina Healthcare Inc. (NYSE: MOH), MEDNAX, Inc. (NYSE: MD), and Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Ariad Pharmaceuticals Inc. Research Report
On January 2, 2014, Ariad Pharmaceuticals Inc. (Ariad) announced that it will be presenting at the 32nd Annual J.P. Morgan Healthcare Conference to be held in San Francisco. The Company stated that its Chairman and CEO, Harvey J. Berger, M.D., will provide the Company's business overview on Tuesday, January 14, 2014 at 3:00 p.m. PT. Ariad added that the presentation will be webcast live and can be accessed via the Investor Relations section of the Company's website, with a replay of the presentation to be available and archived on the website for three weeks. The Full Research Report on Ariad Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Salix Pharmaceuticals Ltd. Research Report
On January 2, 2014, Salix Pharmaceuticals, Ltd. (Salix) announced the completion of its acquisition of Santarus, Inc. (Santarus) through a merger. Salix further informed that it has also completed its previously announced tender offer for all outstanding shares of common stock par value $0.0001 per share, including the associated rights to purchase shares of Series A Junior Participating Preferred Stock, par value $0.0001 per share, of Santarus, at a purchase price of $32.00 per share, net to the seller in cash, without interest thereon and subject to any required withholding taxes. Carolyn Logan, Salix President and CEO, commented, "The acquisition of Santarus is a transformational event for Salix and an important milestone in our growth as the leading gastroenterology-focused specialty pharmaceutical company in the United States. The creation of a larger, stronger Salix reinforces our premier position in gastroenterology and creates the opportunity for us to expand our digestive disease expertise into other key specialties." The Full Research Report on Salix Pharmaceuticals Ltd. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Molina Healthcare Inc. Research Report
On January 2, 2014, Molina Healthcare Inc.'s (Molina) stock rose to end the day at $36.15, compared to the previous day's closing price of $34.75, a 4.03% rise. The Company's stock rose 8.85% over the past three trading days, compared to the Dow Jones Industrial Average Index which went down by 0.22% over the same trading period. The Full Research Report on Molina Healthcare Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
MEDNAX, Inc. Research Report
On January 2, 2014, MEDNAX, Inc. (Mednax) announced that it has acquired Summit Anesthesia Associates, P.A., a physician group practice based in New Jersey. According to the Company, the practice will become part of Mednax's American Anesthesiology division. Glen Paris, M.D., who will serve as medical director for the practice, stated, "Joining American Anesthesiology is a great fit for us, both clinically and culturally because our goals are very much aligned. American Anesthesiology's clinical research, education and quality initiatives will serve to further support the high quality care we have provided our patients for more than 20 years. And, the stability of a national medical group with a reputation for strong back-office infrastructure and efficiencies will enhance our business operations, as our country's healthcare environment continues to become more complex." The Company added that this was a cash transaction, and is expected to be immediately accretive to Mednax's earnings. The Full Research Report on MEDNAX, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Merrimack Pharmaceuticals, Inc. Research Report
On January 2, 2014, Merrimack Pharmaceuticals, Inc.'s (Merrimack) stock rose 4.88% to end the day at $5.59. The Company's stock advanced 8.33% over the past three trading days, compared to the Dow Jones Industrial Average Index which went down by 0.22% over the same trading period. The Full Research Report on Merrimack Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.http://www.AnalystsCorner.com
SOURCE Analysts' Corner